Evotec Announces Phase I Initiation with P2X7 Antagonist
News Oct 10, 2008
Evotec AG has announced that Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist have been initiated.
The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines. P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions, which affect millions of individuals.
The first Phase I study is a double-blind and placebo-controlled single ascending dose study in healthy male volunteers to evaluate the compound’s safety, tolerability, pharmacokinetic profile and pharmacodynamic effects after oral administration.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019